Skip to main contentrtttttt Skip to main content
Integrative Psychiatry

The Best Ways to Stay Updated on the Latest Psychedelic News & Research

The field of psychedelic-assisted therapy is evolving rapidly, with new research, clinical trials, and policy changes emerging frequently. Whether you’re a practitioner, researcher, or enthusiast, keeping up with the latest findings is essential to staying informed and effective in this space.

Below, we’ve compiled the top 10 most reliable resources for psychedelic news and research, along with instructions on setting up Google Alerts so you can receive real-time updates tailored to your interests.

Top 10 Psychedelic News & Research Resources

Here are some of the best sources to stay ahead of the latest developments:

      • Regularly updated with research findings on psychedelic substances and their therapeutic applications.
      • Research updates and discussions on psychedelics from one of the world’s top universities.
      • Subscribe to their excellent weekly Substack “The Microdose”
      • Psychedelics Business news updated daily
      • A peer-reviewed journal covering the psychological, biological, and social aspects of psychedelic substances.
      • A nonprofit leading the way in MDMA-assisted therapy research for PTSD and psychedelic policy reform.
      • Covers cutting-edge clinical research on psychedelics in psychiatry and neurology.
      • One of the leading institutions studying psilocybin for depression, anxiety, and addiction.
    • Focused on research, education, and the therapeutic potential of psychedelics.

How to Set Up Google Alerts for Psychedelic News

To automate your research updates, you can create Google Alerts to receive new articles, studies, and policy changes directly in your inbox. Here’s how:

Step 1: Visit Google Alerts

Go to Google Alerts.

Step 2: Enter Your Search Terms

To get the most relevant results, enter search phrases related to psychedelics, such as:

General Psychedelic Science & Research

  • “Psychedelic therapy clinical trials”
  • “Psychedelic research findings”
  • “Entourage effect psychedelics”

Plant-Based Psychedelics

  • “Psilocybin mushrooms clinical research”
  • “Ayahuasca mental health research”
  • “Ibogaine addiction treatment research”

Pharmaceutical Psychedelics

  • “Synthetic psilocybin FDA trials”
  • “MDMA-assisted therapy approval”
  • “LSD microdosing clinical studies”
  • “Ketamine therapy for depression”

Regulations & Policy Updates

  • “Psychedelic legalization news”
  • “FDA psychedelic drug approval”
  • “DEA psychedelic scheduling changes”

Leading Organizations & Institutions

  • “Johns Hopkins psychedelics research”
  • “MAPS MDMA research”
  • “UC Berkeley psychedelics research”

Step 3: Customize Your Alert Preferences

  • Frequency: Choose “As-it-happens” for real-time updates or “Once a day” for a daily summary.
  • Sources: Select “News,” “Blogs,” or “Scientific Publications” for high-quality updates.
  • Region: If you want updates from specific countries, adjust this setting.
  • Language: Set your preferred language for alerts.

Step 4: Create the Alert

Click “Create Alert”—and you’re done! You’ll now receive curated updates on psychedelic news and research straight to your inbox.

Final Thoughts

With the rapid growth of psychedelic-assisted therapy, staying informed is crucial for practitioners, researchers, and anyone passionate about this space. By following some of the best top 10 research sources and setting up Google Alerts, you’ll be well-equipped to track the latest breakthroughs, policy changes, and clinical advancements in plant and pharmaceutical psychedelics.

Sara Reed, MS, LMFT

Sara Reed is a Licensed Marriage and Family Therapist and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. As a mental health futurist and clinical researcher, Sara examines the ways culture informs the way we diagnose and treat mental illness. Sara’s prior research work includes participation as a study therapist in psychedelic therapy research at Yale University and the University of Connecticut’s Health Center. Sara was the first Black therapist to provide MDMA-assisted psychotherapy in a clinical trial and continues to engage in ongoing advocacy work around health equity in psychedelic medicine.

https://psychiatryinstitute.com/wp-content/uploads/2019/11/Jeffrey-Guss.png

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy and the treatment of substance use disorders. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psychedelic-assisted psychotherapy in the treatment of cancer-related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psychedelic-Assisted therapy in the treatment of Alcoholism, a collaborator with Yale University’s study on psychedelic-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS (Multidisciplinary Association for Psychedelic Studies) study on treatment of Post Traumatic Stress Disorder with Psychedelic-Assisted Psychotherapy. 

Dr. Guss is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He has published (with Elizabeth Nielson, PhD) a paper on “the influence of therapists’ first had experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training” in The Journal of Psychedelic Studies, August, 2018. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies and Supervisor in NYU’s Fellowship in Addiction Psychiatry. 

Dr. Guss maintains a private practice in New York City.

Will Van Derveer, MD

Will Van Derveer, MD is Co-Founder of Integrative Psychiatry Institute and Integrative Psychiatry Centers. Dr. Van Derveer was co-investigator on a phase 2 MAPS study of Psychedelic-assisted psychotherapy for treatment-resistant PTSD, and co-authored the publication of this study in 2018. He has also provided Psychedelic-assisted psychotherapy in two MAPS training studies. An active provider of KAP at his clinic in Boulder, CO, he has been teaching others KAP therapy for several years. Dr. Van Derveer contributed a chapter on mescaline in the 2021 "Handbook of Medical Hallucinogens" (edited by Charles Grob and Jim Grigsby). He is co-host of the Higher Practice Podcast.

Dr. Van Derveer regards unresolved emotional trauma as the most significant under-recognized root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass.


Scott has been a student of consciousness since his honors thesis on that topic at the University of Arizona in the 1970s under the tutelage of Dr. Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. Psychedelic-assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.

In 2010 he founded Wholeness Center in Fort Collins. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principal Investigator and therapist for the Phase III trial of psychedelic-assisted psychotherapy for PTSD sponsored by (MAPS). He has also published numerous articles about his research on (CBD) in mental health. Currently, Scott works extensively with psychedelic-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools, and a paradigm-shifting perspective about transformative care.

Will Van Derveer, MD is co-founder of Integrative Psychiatry Institute (IPI), along with friend and colleague Keith Kurlander, MA. He co-created IPI as an expression of what he stands for. First, that anyone can heal, and second that we medical providers must embrace our own healing journeys in order to fully command our potency as healers.

Dr. Van Derveer spent the last 20 years innovating and testing a comprehensive approach to addressing psychiatric challenges which transcends the conventional model he learned in medical school at Vanderbilt University and residency at University of Colorado, while deeply engaging his own healing path.

He founded the Integrative Psychiatric Healing Center in in 2001 in Boulder, CO, where he currently practices. Dr. Van Derveer regards unresolved emotional trauma as the most significant root cause of psychiatric symptoms in integrative psychiatry practice, along with gut issues, hormone imbalances, inflammation, mitochondrial dysfunction, and other functional medicine challenges. He is trained in Somatic Experiencing, EMDR, Internal Family Systems, and other psychotherapy techniques. His current clinical passion is psychedelic-assisted psychotherapy, which he mentors interested doctors in providing. An avid meditator, he has been a meditation instructor since 2004.

For the past several years Dr. Van Derveer has taught psychiatrists and other psychiatric providers integrative psychiatry in a number of settings, including course directing the CU psychiatry residents’ course as well as with Scott Shannon and Janet Settle at the Psychiatry MasterClass. In addition to his clinical work and teaching, he was co-investigator in 2016 a Phase II randomized clinical trial, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). He continues to support this protocol, now in a Phase III clinical trial under break-through designation by FDA.

Dr. Van Derveer is a diplomate of the American Board of Integrative and Holistic Medicine (ABoIHM) since 2013, and he was board certified in the first wave of diplomates of the new American Board of Integrative Medicine (ABIM) in 2016.